Radar · Life Sciences in Boston
Best Life Sciences Companies in Boston, United States
The 537 best Life Sciences companies in Boston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Intarcia.
By Riya SenguptaFinancials
537companies tracked
$21.9Bdisclosed funding
6unicorns
339have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × BOSTON
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
383kcombined LinkedIn audience
31%of audience held by top 3
8companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Boston
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Ginkgo Bioworks 🦄 Autonomous labs for biotechnology, empowering scientists to design the living world | $796M | 30 mo ago | Public | 1,218 | Austin Che Co-Founder | 385 patents Engineering microbes for biosynthesis of drugs, flavors, proteins, and immune therapeutics | — |
| 2 | Fog Pharmaceuticals Developer of cell-penetrating mini-proteins to target intracellular disease drivers | $531M | 27 mo ago | Series E | 97 97 → 197 (+103%) | — | — | 1 partnership |
| 3 | Scorpion Developer of drugs for the treatment of cancer | $420M | 13 mo ago | Series C | 62 | — | — | — |
| 4 | Aktis Oncology Developer of radiopharmaceuticals for solid tumor cancers | $336M | 20 mo ago | Public | 15 | — | 26 patents Targeted cancer therapeutics using engineered miniprotein ligands and conjugates | — |
| 5 | Seaport Therapeutics Developer of therapeutics to treat neuropsychiatric disorders | $325M | 19 mo ago | Public | — | Steven Paul Co-Founder | — | 1 award |
| 6 | Dewpoint Therapeutics Developer of small molecule based therapeutics 53Funding top 17%Moat top 31%Talent top 38%News top 41% All 7 signals ▾Fundingtop 17% Moattop 31% Talenttop 38% Newstop 41% Markettop 45% Globalbottom 45% Techbottom 32% Funding: Raised $287M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 53/100 | $287M | 9 mo ago | Series D | 147 | Richard Young Co-Founder | — | 1 job opening |
| 7 | Beta Bionics Innovating diabetes management with automated bionic pancreas technology | $283M | 19 mo ago | Public | 92 | — | 208 patents Wearable closed-loop insulin/glucagon patch pump systems and dosing algorithms for diabetes | — |
| 8 | Cardurion Developer of therapeutics for heart and cardiovascular diseases | $270M | 23 mo ago | Series B | 34 | — | — | 1 award |
| 9 | Alpha-9 Oncology Developer of radiopharmaceuticals for the treatment of cancer | $261M | 19 mo ago | Series C | — | David Hirsch CEO | — | — |
| 10 | Emulate Developer of in vitro models for drug development 78Funding top 15%Patents top 25%Moat top 26%Innovation top 34% All 10 signals ▾Fundingtop 15% Patentstop 25% Moattop 26% Innovationtop 34% Techtop 34% Growthtop 40% Markettop 45% AItop 45% Globalbottom 49% Newsbottom 22% Funding: Raised $225M across 10 rounds · 10 rounds over 12 yrs (0.8/yr) Patents: 479 patents matched (strict assignee match) · 170 filings since 2022 vs 309 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $225M | 8 mo ago | Series E | 103 103 → 71 (-31%) | — | 479 patents Microfluidic organ‑on‑chip platforms for tissue modeling and drug screening | 1 job opening |
| 11 | CervoMed Developer of therapeutics for neurodegenerative diseases | $209M | 15 mo ago | Public | 13 13 → 20 (+54%) | John Alam Co-Founder & CEO | — | — |
| 12 | Third Arc Bio Developer of therapetics for cancer and immunological diseases 37Funding top 20%Talent top 38%Moat bottom 48%Tech bottom 47% All 7 signals ▾Fundingtop 20% Talenttop 38% Moatbottom 48% Techbottom 47% Globalbottom 36% Marketbottom 32% Newsbottom 18% Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $165M | 4 mo ago | Series A | — | Sanjaya Singh Founder & Chief Scientific Officer | — | — |
| 13 | Elektrofi Digital platform transforming the delivery of biologic medicines | $152M | 22 mo ago | Acquired | 62 | Chase Coffman Co-Founder & CEO | 81 patents Dry pharmaceutical particle manufacturing for drug delivery via continuous droplet formation. | 4 job openings |
| 14 | Life Biosciences Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases 53Funding top 16%Growth top 28%Moat top 31%News top 43% All 7 signals ▾Fundingtop 16% Growthtop 28% Moattop 31% Newstop 43% Techtop 49% Globalbottom 39% Marketbottom 33% Funding: Raised $150M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $150M | 2 mo ago | Series D | 14 14 → 27 (+93%) | — | — | — |
| 15 | Aprea Developer of small molecule therapeutics targeting tumor suppressor proteins 40Funding top 18%Growth top 30%News top 38%Moat top 48% All 7 signals ▾Fundingtop 18% Growthtop 30% Newstop 38% Moattop 48% Globalbottom 42% Techbottom 35% Marketbottom 25% Funding: Raised $113M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $113M | 6 mo ago | Public | 13 | — | — | — |
| 16 | Atalanta Therapeutics Developer of RNAi therapeutics to treat neurodegenerative diseases | $110M | 16 mo ago | Series B | 62 | Neal Aronin Co-Founder | — | — |
| 17 | TetraScience Provider of a cloud-based data platform for life science industry 40Funding top 21%Growth top 26%Moat top 35%Tech top 50% All 9 signals ▾Fundingtop 21% Growthtop 26% Moattop 35% Techtop 50% Newsbottom 47% Globalbottom 39% Marketbottom 38% Patentsbottom 25% Innovationbottom 22% Funding: Raised $99.2M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Growth: Headcount 13 → 30 (+131%) across vintages · Web rank 5,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 40/100 | $99M | 4 mo ago | Series B | 30 | — | 4 patents Real-time monitoring and feedback control systems for industrial tools and equipment | 1 job opening |
| 18 | X4 Pharmaceuticals Developer of small molecule drugs for the treatment of cancer | $98M | 10 mo ago | Public | 70 70 → 79 (+13%) | — | 437 patents Immunomodulatory small‑molecule drugs targeting CXCR4/CXCR2, BTK, IL‑6 and complement pathways. | — |
| 19 | Newleos Developer of oral small molecules for neuropsychiatric conditions treatment | $94M | 16 mo ago | Series A | — | Federico Bolognani Chief Medical Officer and co-Founder | — | — |
| 20 | GRO Biosciences Developer of re-coding synthetic biology tools | $91M | 23 mo ago | Series B | 22 | Daniel Mandell CEO | — | — |
| 21 | Cytrellis Developer of aesthetic devices for scar reduction and skin tightening | $86M | 17 mo ago | Series C | 59 59 → 59 (+0%) | Jason Richey President & Chief Executive Officer | — | 1 internship |
| 22 | Stylus Medicine Developer of gene-based therapeutics for multiple diseases | $85M | 13 mo ago | Series A | 21 | — | — | — |
| 23 | AcuityMD Platform offering CRM software to the medical industry 53Funding top 18%News top 25%Talent top 28%Growth top 35% All 10 signals ▾Fundingtop 18% Newstop 25% Talenttop 28% Growthtop 35% Producttop 36% Moattop 39% Techtop 48% Marketbottom 42% Innovationbottom 37% Globalbottom 34% Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | Series C | 48 | Michael Monovoukas Co-Founder & CEO | — | — |
| 24 | Corsera Health Developer of technology predicting and preventing cardiovascular disease before it begins 72Funding top 24%Talent top 28%AI top 45%Global bottom 48% All 4 signals ▾Fundingtop 24% Talenttop 28% AItop 45% Globalbottom 48% Funding: Raised $80.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $80M | 5 mo ago | Series A | — | Chris Cox Co-Founder | — | — |
| 25 | Miach Orthopaedics Developer of surgical implants for connective tissue repair 64Funding top 23%Talent top 28%Patents top 32%Moat top 32% All 10 signals ▾Fundingtop 23% Talenttop 28% Patentstop 32% Moattop 32% Growthtop 35% Innovationtop 39% Techtop 48% Marketbottom 46% Globalbottom 42% Newsbottom 22% Funding: Raised $72.5M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) Talent: Analyst team rating 5/5 · 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 64/100 | $72M | 1 mo ago | Series B | 46 | Martha Murray Founder | 33 patents Injectable collagen biomaterials for orthopedic tissue repair and regeneration | — |
| 26 | Kinaset Therapeutics Developer of therapeutics to treat asthma 24Funding top 26%Talent top 28%Moat top 39%Global bottom 38% All 6 signals ▾Fundingtop 26% Talenttop 28% Moattop 39% Globalbottom 38% Marketbottom 26% Techbottom 26% Funding: Raised $68.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 24/100 | $68M | 5 mo ago | Series B | 10 | Frazer Morgan Co-Founder | — | — |
| 27 | Hillstar Bio Developer of precision immunotherapies for autoimmune diseases | $67M | 14 mo ago | Series A | — | Robert Mabry CEO | — | — |
| 28 | Centrexion Developer of drugs for chronic pain management | $66M | 12 mo ago | Public | 14 | Sol Barer Founder & Chairman | — | — |
| 29 | Ampersand Developer of programmable medicines to treat multiple diseases 42AI top 15%Funding top 24%Talent top 38%Moat top 40% All 10 signals ▾AItop 15% Fundingtop 24% Talenttop 38% Moattop 40% Growthtop 43% Patentsbottom 45% Techbottom 43% Globalbottom 38% Innovationbottom 30% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) Funding: Raised $65.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $65M | 14 mo ago | Series B | 22 | Raffi Afeyan Co-Founder & Chief Innovation Officer | 5 patents Audio signal analysis and filtering, plus multidimensional GUI for database interaction | 1 partnership |
| 30 | Normunity Developer of immunotherapies for the treatment of cancer | $65M | 17 mo ago | Series B | 19 | Lieping Chen Co-Founder | 4 patents Therapeutic antibodies targeting KLK6, LY6K, and PLA2G10 for disease treatment | — |
| 31 | Vicarious Surgical Provider of VR-based surgical robotic system for physicians | $43M | 8 mo ago | Public | 131 | Sammy Khalifa Co-Founder and CTO | 174 patents Robotic surgical systems: instrument exchange, force feedback, vision, and control interfaces. | — |
| 32 | Arietis Developing novel antibiotics to combat drug-resistant bacterial pathogens and infections | $41M | 14 mo ago | Funding Raised | 5 | Kim Lewis Founder | 2 patents Antimicrobial agents targeting dormant/non-replicating bacterial infections | — |
| 33 | InspireMD Stents integrated with a bio-stable mesh | $34M | 10 mo ago | Public | 66 66 → 121 (+83%) | — | — | — |
| 34 | Solu Therapeutics Developer of therapeutics for oncology and immunology diseases | $31M | 14 mo ago | Series A | 9 | John Pribis Co-founder | — | — |
| 35 | Pi Health Provider of an AI-native platform for managing clinical trials end-to-end 62Patents top 20%Moat top 21%Growth top 28%Innovation top 31% All 11 signals ▾Patentstop 20% Moattop 21% Growthtop 28% Innovationtop 31% Fundingtop 31% Talenttop 38% AItop 45% Techbottom 47% Globalbottom 45% Marketbottom 29% Newsbottom 18% Patents: 9,865 patents matched (strict assignee match) · 2246 filings since 2022 vs 3287 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 9,865 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $31M | 4 mo ago | Series A | — | Bobby Reddy Md Co-Founder and COO | 9,865 patents Cell-based immunotherapies, engineered NK/CAR cells, and PET imaging agents for oncology | 1 job opening |
| 36 | AOA Provider of an AI-enabled early detection platform focused on womens health 45Funding top 24%Patents top 27%Talent top 28%Innovation top 33% All 8 signals ▾Fundingtop 24% Patentstop 27% Talenttop 28% Innovationtop 33% Moattop 47% Globalbottom 44% Marketbottom 21% Newsbottom 18% Funding: Raised $30.7M across 7 rounds · 7 rounds over 5 yrs (1.4/yr) Patents: 22 patents matched (strict assignee match) · 21 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $31M | 8 mo ago | Series A | 3 | Alex Fisher Co-Founder & COO | 22 patents Patents concentrated in health & consumer products | 1 award |
| 37 | Sensorium Therapeutics Developer of therapeutics for psychiatric and neurological disorders | $30M | 13 mo ago | Series A | 23 | Alex Simon Co-Founder | — | — |
| 38 | 4D Path Developer of precision medicines for the treatment of cancer 35Talent top 28%Patents top 31%Funding top 37%Moat top 38% All 8 signals ▾Talenttop 28% Patentstop 31% Fundingtop 37% Moattop 38% Innovationtop 41% Techbottom 38% Globalbottom 37% Marketbottom 23% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $17M | 1 mo ago | Series B | 10 | Rodrigo Navarro Co-Founder & CEO & President | 46 patents Lipid‑nanoparticle delivery systems for malaria vaccines and encapsulated therapeutics | 2 partnerships |
| 39 | Syntis Provider of drug compounding services | $15M | 11 mo ago | Series A | 9 | Robert Langer Co-Founder | — | — |
| 40 | Genialis Developer of end-to-end bioinformatics software solutions 53Funding top 33%Growth top 35%Moat top 37%Patents top 38% All 10 signals ▾Fundingtop 33% Growthtop 35% Moattop 37% Patentstop 38% Innovationtop 39% Talenttop 41% Producttop 46% Techtop 50% Globalbottom 44% Marketbottom 35% Funding: Raised $15.3M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $15M | 6 mo ago | Series A | 35 | Rafael Rosengarten Chief Executive Officer | 17 patents Patents concentrated in computing, sensing & instrumentation | 1 launch |
| 41 | PhaseV DIgital platform for clinical trial design and closed-loop execution | $15M | 13 mo ago | Series A | 15 | — | — | — |
| 42 | Micro Leads Precision neuromodulation therapies using minimally-invasive, high-resolution devices for nervous system… | $15M | 14 mo ago | Seed | 12 | — | — | — |
| 43 | Phylo Developer of collaborative agents designed for biologists to accelerate discoveries 42Funding top 32%Talent top 38%Tech top 40%Market bottom 37% All 5 signals ▾Fundingtop 32% Talenttop 38% Techtop 40% Marketbottom 37% Globalbottom 33% Funding: Raised $13.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $14M | 4 mo ago | Seed | — | Yuanhao Qu Co-Founder & President | — | 1 launch · 3 partnerships |
| 44 | Modulight Biotherapeutics Developer of an optogenetic platform targeting pathological neural activity to restore balance | $12M | 7 mo ago | Seed | — | Ofer Yizhar Co-Founder & CSO | — | 1 award |
| 45 | Adeptrix Developer of bead-assisted mass spectroscopy technology for proteomics | $10M | 13 mo ago | Series A | 7 | — | 29 patents Multiplexed bead-based immunoassay platforms for high-throughput protein/biomarker analysis | 2 launchs |
| 46 | Skeletalis Developer of targeted small-molecule therapies for musculoskeletal health and bone regeneration 37Talent top 38%Funding top 43%Global bottom 33% All 3 signals ▾Talenttop 38% Fundingtop 43% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $8.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $8M | 7 mo ago | Series A | — | Benton Swanson Co-Founder & CEO | — | — |
| 47 | NeoSoma Provider of an AI-based image analysis and decision-making platform for neurooncologist 40AI top 28%Funding top 40%Patents top 40%Moat top 42% All 8 signals ▾AItop 28% Fundingtop 40% Patentstop 40% Moattop 42% Innovationtop 48% Talentbottom 49% Globalbottom 35% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) · Product described with: ai-based Funding: Raised $6.3M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $6M | 3 mo ago | Series B | 13 | Ken Kolodziej Co-Founder & CEO | 7 patents AI-driven MRI segmentation and volumetric analysis of high-grade brain gliomas | — |
| 48 | Tiba Biotech Provider of fully synthetic RNA vaccine drug delivery technology | $6M | 9 mo ago | Funding Raised | 16 | Christian W Mandl Co-Founder | 58 patents Patents concentrated in health & consumer products | — |
| 49 | Predicta Biosciences Provider of diagnostic and therapeutic products for oncology | $5M | 8 mo ago | Series A | — | Gad Getz Co-Founder | — | 2 partnerships · 1 award |
| 50 | Outpost Bio Developer of artificial intelligence to analyze microbial ecosystems for medicine | $4M | 3 mo ago | Seed | — | Alex Merwin Co-Founder & COO | — | 1 award |
Top 12 Life Sciences companies in Boston
#1
Series D · Boston, Massachusetts · founded 2017 · 14 employees$150.2Mraised▾
Series D · Boston, Massachusetts · founded 2017 · 14 employees
Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases. The company is focused on targeting the biology of aging, which is the biggest risk factor for most chronic diseases. They are developing a novel partial epigenetic reprogramming platform that targets a key underlying mechanism of aging to prevent and reverse age-related diseases with significant unmet need to extend healthy human lifespan. This approach holds the promise of treating many of the most debilitating and chronic diseases. The platform builds on innovative science from world-leading researchers to partially reprogram the epigenome of aged and injured cells to restore cellular function to a younger state. This is a B2B model.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%Growth
top 28%Moat
top 31%News
top 43%Tech
top 49%Global
bottom 39%Funding: Raised $150M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) · Last round Series D (Apr 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 13k LinkedIn followers — 3.5% of this cohort's audience
Funding rounds
- Apr 2026Series D$80M
- Nov 2025Series C$31M
- Jan 2022Series C$82M
- Jun 2020Series B$18.2M
Investors
Alpha Wave Global, The Longevity Fund, National Science Foundation, Abundance Partners, Wynwood Projects, Globalive Capital
Tech stack
CloudflareCloudflare Bot ManagementCookieyesGodaddyGoogle AnalyticsGoogle Hosted Libraries
#2
Series B · Boston, Massachusetts · founded 2016 · 46 employees$72.5Mraised▾
Series B · Boston, Massachusetts · founded 2016 · 46 employees
Miach Orthopaedics is developing bio-engineered surgical implants for connective tissue repair. The company has developed a BEAR implant which is a proprietary bio-engineered sponge designed as a bridging scaffold to facilitate healing of the torn ACL (anterior cruciate ligament).
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 23%Talent
top 28%Patents
top 32%Moat
top 32%Growth
top 35%Innovation
top 39%Funding: Raised $72.5M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) · Last round Series B (May 2026)
Talent: Analyst team rating 5/5 · 2 named leaders on record · 2 C-suite/founder profiles curated
Patents: 33 patents matched (strict assignee match) · 33 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 9k LinkedIn followers — 2.4% of this cohort's audience
Funding rounds
- May 2026Series B$6.5M
- Oct 2025Conventional Debt$7.5M
- Apr 2024Series B$20M
- Jan 2023Series B$30M
Founders & team
Investors
SVB, Sectoral, Endeavour Vision, Amzak Health, Smith+Nephew, NFLPA
Tech stack
CloudflareCloudflare Bot ManagementCore-JsCrazy EggFacebook PixelFancybox
#3
Series C · Boston, Massachusetts · founded 2018 · 48 employees$83Mraised▾
Series C · Boston, Massachusetts · founded 2018 · 48 employees
Platform offering CRM software to the medical industry. The platform enables members to personalize customer engagement, identify and quantify opportunities, forecast sales accurately, understand the value of the sales pipeline, empower the sales team, track new launches, understand product adoption and market penetration.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 18%News
top 25%Talent
top 28%Growth
top 35%Product
top 36%Moat
top 39%Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Apr 2026)
News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers — 3.8% of this cohort's audience
Funding rounds
- Apr 2026Series C$80M
- Jun 2024Series B$45M
- May 2022Series A$31M
- May 2021Series A$7M
Founders & team
Investors
Iconiq Capital, Atreides Management, StepStone Group, Redpoint Ventures, Benchmark, Artisanal Ventures
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsFacebook Pixel
#4
Series B · Boston, Massachusetts · founded 2014 · 30 employees$99.2Mraised▾
Series B · Boston, Massachusetts · founded 2014 · 30 employees
Provider of a cloud-based data platform for life science industry. It provides a platform that automatically gathers scientific data from lab equipment, gets data ready for analysis and display, and re-engineers raw or primary data into harmonised data.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 21%Growth
top 26%Moat
top 35%Tech
top 50%News
bottom 47%Global
bottom 39%Funding: Raised $99.2M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) · Last round Series B (Feb 2026)
Growth: Headcount 13 → 30 (+131%) across vintages · Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 8/10 · IP moat: 4 patents · Soonicorn
Audience (LinkedIn): 57k LinkedIn followers — 14.9% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Product Manager
Funding rounds
- Feb 2026Series B$15M
- Apr 2021Series B$80M
- 2020Series A$11M
- Oct 2019Series A$8M
Investors
Underscore VC, Impetus VC, Alkeon Capital Management, Insight Partners, Y Combinator, Founder Collective
Tech stack
6SenseAmazon SesAmazon Web ServicesApple Icloud MailCloudflareCloudflare Bot Management
#5
Series A · Boston, Massachusetts · founded 2022$165Mraised▾
Series A · Boston, Massachusetts · founded 2022
Developer of therapetics for cancer and immunological diseases. It offers multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. It has technology platform a solid tumor synergy platform and an I&I platform fornimmune regulation at a tissue-specific level.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Moat
bottom 48%Tech
bottom 47%Global
bottom 36%Market
bottom 32%Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Feb 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 1/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Adagene) announced in 12 mo
Funding rounds
- Feb 2026Series A$52M
- Jul 2024Series A$165M
Founders & team
Investors
Vida Ventures, Cormorant Asset Management, Hillhouse, Goldman Sachs Asset Management, BVF Partners, Janus Henderson Investors
Tech stack
AosCookieyesCore-JsDocusignGatsbyGodaddy
#6
Series E · Boston, Massachusetts · founded 2013 · 103 employees$225Mraised▾
Series E · Boston, Massachusetts · founded 2013 · 103 employees
Developer of in vitro models for drug development. The company has culture modules, organ-chips, and analytical software applications. The proprietary Organ-Chip models including the liver, intestine, kidney, and others contain tiny hollow channels lined with tens of thousands of living human cells and tissues are designed to predict human response.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 15%Patents
top 25%Moat
top 26%Innovation
top 34%Tech
top 34%Growth
top 40%Funding: Raised $225M across 10 rounds · 10 rounds over 12 yrs (0.8/yr) · Last round Grant (prize money) (Sep 2025)
Patents: 479 patents matched (strict assignee match) · 170 filings since 2022 vs 309 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 8/10 · IP moat: 479 patents · Soonicorn
Audience (LinkedIn): 30k LinkedIn followers — 7.7% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Business Development Executive
Funding rounds
- Sep 2025Grant (prize money)$493K
- Sep 2021Series E$82M
- Mar 2020Conventional Debt$19.3M
- Aug 2019Series C$28M
Investors
Cedars Sinai, OS Fund, ATEL Ventures, LabCorp, ALS, ND Capital
Tech stack
AddtoanyAddtoany Share ButtonsAmazon Web ServicesApple Icloud MailBackbone.JsCloudflare
#7
Public · Boston, Massachusetts · founded 2003 · 13 employees$113.2Mraised▾
Public · Boston, Massachusetts · founded 2003 · 13 employees
Developer of small molecule therapeutics targeting tumor suppressor proteins. The company focuses on p53, a tumor suppressor protein that induces cell cycle arrest or cell death. The company's lead candidate is APR-246, that acts by reactivating mutant and defective native p53, leading to tumor cell death. The company is also developing APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 18%Growth
top 30%News
top 38%Moat
top 48%Global
bottom 42%Tech
bottom 35%Funding: Raised $113M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) · Last round Post IPO (Dec 2025)
Growth: Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 31 tracked, 5 types) · +33% YoY · Top themes: Earnings, Announcements, Funding
Funding rounds
- Dec 2025Post IPO$3.1M
- Mar 2024Post IPO—
- Feb 2023Grant (prize money)$2M
- Feb 2019Series C$5.7M
Investors
Nantahala Capital Management, DAFNA Capital Management, Exome Asset Management, Sphera Fund, Stonepine, Janus Henderson Investors
#8
Series D · Boston, Massachusetts · founded 2018 · 147 employees$287.1Mraised▾
Series D · Boston, Massachusetts · founded 2018 · 147 employees
Dewpoint Therapeutics is involved in development of small molecules based therapeutics. The company offers condensate biology to create dynamic, liquid compartments in cells for the treatment of neurodegeneration, cancer, and other diseases.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 17%Moat
top 31%Talent
top 38%News
top 41%Market
top 45%Global
bottom 45%Funding: Raised $287M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Sep 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 16k LinkedIn followers — 4.2% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Associate Principal / Principal Computational Biologist
Funding rounds
- Sep 2025Series D$59.1M
- Feb 2022Series C$150M
- Sep 2020Series B$77.1M
- Jan 2019Series A$60M
Founders & team
Investors
Polaris Partners, Samsara BioCapital, 6 Dimensions Capital, EcoR1, Alexandria, Leaps by Bayer
#9
Series B · Boston, Massachusetts · founded 2020 · 10 employees$68.5Mraised▾
Series B · Boston, Massachusetts · founded 2020 · 10 employees
Developer of therapeutics to treat asthma. The company's proprietary product includes KN-002 which is an inhibitor of pan-JAK used to treat severe asthma. It is inhaled and delivered to the site of inflammation in the lung and minimizes systemic exposure.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 26%Talent
top 28%Moat
top 39%Global
bottom 38%Market
bottom 26%Tech
bottom 26%Funding: Raised $68.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series B (Jan 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Jan 2026Series B$103M
- Jul 2023Series A$28.5M
- Nov 2020Series A$40M
Founders & team
Investors
5AM Ventures, Atlas Venture, Gimv, EQT, RA Capital Management, Forge Life Science Partners
#10
Series A · Boston, Massachusetts · founded 2024$80Mraised▾
Series A · Boston, Massachusetts · founded 2024
Developer of technology predicting and preventing cardiovascular disease before it begins. The company utilizes science and artificial intelligence for cardiovascular wellness. It aims to empower people to live healthier and longer lives.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 24%Talent
top 28%AI
top 45%Global
bottom 48%Funding: Raised $80.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Jan 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
AI: Product described with: artificial intelligence
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Jan 2026Series A$80M
Founders & team
Investors
Forbion, Population Health Partners
#11
Series B · Boston, Massachusetts · founded 2016 · 10 employees$17.1Mraised▾
Series B · Boston, Massachusetts · founded 2016 · 10 employees
4D Path is a developer of precision medicines for the treatment of cancer. It has developed medicines for cancer diagnosis and it provides therapeutic molecular overexpression profiles. It has developed precision diagnostics solutions that help in identify cancer types, subtypes, variants & mimics, surgical margin, and others.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 28%Patents
top 31%Funding
top 37%Moat
top 38%Innovation
top 41%Tech
bottom 38%Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 · Latest publication 2025
Funding: Raised $17.1M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (May 2026)
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. VCTS) announced in 12 mo
Funding rounds
- May 2026Series B—
- May 2023Series B$13M
- Jul 2020Series A$4.1M
Founders & team
Tech stack
AosAzureBootstrapCdnjsCloudflareCookieyes
#12
Series C · Boston, Massachusetts · founded 2020 · 62 employees$420Mraised▾
Series C · Boston, Massachusetts · founded 2020 · 62 employees
Developer of drugs for the treatment of cancer. The company aims to develop next-generation targeted therapy for untreatable/ treatment-resistant cancer.
Funding rounds
- May 2025Series C$30M
- Jul 2024Series C$150M
- Jan 2021Series B$162M
- Oct 2020Series A$108M
Investors
Boxer Capital, EcoR1, Vida Ventures, Omega Funds, Invus, Citadel
Funding & investor landscape
$21.9Btotal disclosed funding
339companies funded
1,151disclosed rounds
4rounds last 90 days
Most active investors
Notable founders
Martha Murray
Founder · Miach Orthopaedics
Patrick McBrayer
President & CEO · Miach Orthopaedics
Michael Monovoukas
Co-Founder & CEO · AcuityMD
Robert Coe
Co-Founder & CTO · AcuityMD
Sanjaya Singh
Founder & Chief Scientific Officer · Third Arc Bio
Peter Lebowitz
CEO · Third Arc Bio
Richard Young
Co-Founder · Dewpoint Therapeutics
Ameet Nathwani
Chief Executive Officer · Dewpoint Therapeutics
Frazer Morgan
Co-Founder · Kinaset Therapeutics
Roger Heerman
Co-Founder · Kinaset Therapeutics
Chris Cox
Co-Founder · Corsera Health
Clive Meanwell
Co-Founder & Co-CEO · Corsera Health
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN BOSTON · Health & Bio
How research on Biotechnology in Boston is moving
A read on the academic research around Biotechnology in Boston — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 88 papers.
Boston Children's Hospital and Boston University lead RNA modification, splicing, and CRISPR research across 88 papers, with optimistic breakthrough-dominant findings tempered by modest concern.
88 papers · stance +0.53 · 44% breakthrough · 13% concern
top institutions
- Boston Children\'s Hospital35
- Boston University24
- Boston Children\'s Museum9
- University of Massachusetts Boston7
- Boston VA Research Institute5
leading researchers
Adam Sychla · Bruce Cosgrove · Cary N. Weiss · Peng Lyu · Silvi Rouskin · Vijay G. Sankaran
prism intelligence · tone & topics
92% positive · 0% critical tone
Medical ResearchPharmaceuticalsHealthGeneticsHealthcareBiology
▲
Breakthroughs34 · 39%
▼ 43%→37% share
▼0.9× share momentum0 median citations65% since 2021mostly empirical
Cell biology and in vivo gene research intensifying — each gained 5, 5, and 4 papers as Breakthroughs' share fell from 43% to 37%.
rising sub-themes (early→recent)
- Cell biology5
- In vivo5
- Gene4
- RNA-binding protein3
- Messenger RNA3
Newly emergingCell 0→3
Landmark Reconstituting Organ-Level Lung Functions on a Chip · 4,038 cites
◆
Advancements33 · 38%
▲ 35%→37% share
▲1.1× share momentum0 median citations67% since 2021mostly empirical
Haematopoiesis and somatic cell research rising — each gaining 3 papers as Advancements' share grew from 35% to 37%.
rising sub-themes (early→recent)
- Haematopoiesis3
- Somatic cell3
- Epigenetics2
- Disease2
- Healthy aging2
Landmark Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice · 1,441 cites
▼
Concerns10 · 11%
▼ 17%→10% share
▼0.6× share momentum1 median citations60% since 2021mostly empirical
Concerns cooling overall — field-share dropped 17% to 10% despite antimicrobial stewardship and psychological intervention each adding 2 papers.
rising sub-themes (early→recent)
- Antimicrobial stewardship2
- Psychological intervention2
- In vivo2
- Epidemiology1
- Multidisciplinary approach1
Landmark Biphasic Dose Response in Low Level Light Therapy · 1,105 cites
Common questions
How many Life Sciences companies are there in Boston, United States?
Radar tracks 537 indexable Life Sciences companies headquartered in Boston, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Boston, United States?
The Life Sciences companies in Boston, United States on this list have raised a combined $21.9B in disclosed equity funding across 339 funded companies.
Which is the highest-funded Life Sciences company in Boston, United States?
Intarcia is the highest-funded Life Sciences company in Boston, United States, with $1.9B in disclosed equity funding.
How many Life Sciences companies in Boston, United States are funded?
339 of the 537 Life Sciences companies in Boston, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Boston, United States?
6 Life Sciences companies in Boston, United States on this list are valued at $1B or more.
Who are the top investors in Boston, United States Life Sciences companies?
The most active investors in Boston, United States Life Sciences companies on this list include HHS, MassChallenge, National Science Foundation, RA Capital Management, NIH.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.